Menu
Recruiting NCT05469984

Comparing Two Prophylactic Antibiotic Protocols in Women With Term Prolonged Pre-labor Rupture of Membrane and Preterm Labor

No phase Interventional Preterm Labor With Preterm Delivery Premature Rupture of Membranes Prolonged

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Ampicillin Only Product, ampicillin plus gentamicin.
Who it may be relevant to
Registry conditions: Preterm Labor With Preterm Delivery, Premature Rupture of Membranes Prolonged. Basic parameters: 18 years — 48 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Israel
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparing Obstetrical Outcomes and Infectious Morbidity Between Two Prophylactic Antibiotic Protocols in Women With Term Prolonged Pre-labor Rupture of Membrane and Preterm Labor

Overview

This randomized prospective trial aimed to compare 2 prophylactic antibiotic regiment (ampicillin alone versus ampicillin plus gentamycin) in term prolonged pre-labor rupture of membrane and in preterm deliveries and examine related obstetrical outcome and infectious morbidity

Detailed description

Maternal peripartum fever is a common complication of pregnancy and postpartum period associated with potentially serious obstetrical outcomes and infectious morbidity. Peripartum infections includes intrapartum intraamniotic infection (IAI) and postpartum endometritis. Both are caused by polymicrobial bacterial infection. Increased latency period from rupture of membranes (ROM) until delivery is a common risk factor. Another risk factor is pre-term delivery.

This randomized prospective trial aimed to compare 2 prophylactic antibiotic regiment (ampicillin alone versus ampicillin plus gentamycin) in term prolonged pre-labor rupture of membrane and in preterm deliveries and examine related obstetrical outcome and infectious morbidity.

Primary outcome-peripartum infections- chorioamnionitis, endometritis and surgical site infection secondary outcome- obstetrical outcome- mode of delivery, Apgar score, cord blood pH, peripartum fever, maternal length of admission, postpartum maternal antibiotic treatment, Surface swab cultures were obtained from the placenta, amnion and umbilical cord (birth cultures) and uterine swab cultures, maternal blood culture, placental histologic evaluation neonatal outcomes-NICU admission, length of admission, neonatal morbidity-ventilation support, early neonatal sepsis

Interventions

  • Drug Ampicillin Only Product
    women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
  • Drug ampicillin plus gentamicin
    women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin

Primary outcome measures

  • endometritis rate [Time frame: up to 6 weeks postpartum]
  • chorioamnionitis rate [Time frame: during labor (up to delivery of the newborn)]
Secondary outcome measures (8)
  • cord blood pH [Time frame: immediately after delivery of the placenta]
  • maternal intrapartum fever [Time frame: during labor (up to delivery of the newborn)]
  • NICU (neonatal intensive care unit) hospitalization length, [Time frame: up to 3 month from delivery]
  • rate of neonatal early onset sepsis [Time frame: up to one week from delivery]
  • Rate of participants treated with antibiotics during the postpartum period [Time frame: 6 week postpartum]
  • maternal postpartum hospitalization length [Time frame: up to 6 weeks post partum]
  • Number of neonate with ventilation support [Time frame: one week from delivery]
  • Number of neonate treated with antibiotics [Time frame: one week from delivery]

Eligibility criteria

Inclusion Criteria: maternal age > 18 years singleton pregnancy vertex presentation prolonged >18 h prom or preterm delivery

\-

Exclusion criteria

  • GBS carrier
  • preterm premature rupture of membrane for conservative treatment
  • intra-uterine fetal death fetal major anomaly
  • drug allergy for the antibiotic in use in this study
  • women receiving antibiotic treatment for other infection such as urinary tract infection

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Prevention

Study locations

Israel · 1 center
  • Galil Medical Center — Nahariya

Publications

  • Apantaku O, Mulik V. Maternal intra-partum fever. J Obstet Gynaecol. 2007 Jan;27(1):12-5. doi: 10.1080/01443610601016644. PMID 17365450
  • Committee Opinion No. 712: Intrapartum Management of Intraamniotic Infection. Obstet Gynecol. 2017 Aug;130(2):e95-e101. doi: 10.1097/AOG.0000000000002236. PMID 28742677
  • Kachikis A, Eckert LO, Walker C, Bardaji A, Varricchio F, Lipkind HS, Diouf K, Huang WT, Mataya R, Bittaye M, Cutland C, Boghossian NS, Mallett Moore T, McCall R, King J, Mundle S, Munoz FM, Rouse C, Gravett M, Katikaneni L, Ault K, Klein NP, Roberts DJ, Kochhar S, Chescheir N; Brighton Collaboration Chorioamnionitis Working Group. Chorioamnionitis: Case definition & guidelines for data collection PMID 31783982
  • Yoon BH, Romero R, Moon JB, Shim SS, Kim M, Kim G, Jun JK. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol. 2001 Nov;185(5):1130-6. doi: 10.1067/mob.2001.117680. PMID 11717646
  • Soper DE, Mayhall CG, Froggatt JW. Characterization and control of intraamniotic infection in an urban teaching hospital. Am J Obstet Gynecol. 1996 Aug;175(2):304-9; discussion 309-10. doi: 10.1016/s0002-9378(96)70139-4. PMID 8765246

Identifiers

NCT: NCT05469984 · 0103-22-NHR

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗